Tongkat Ali is NOT Safe for This Patient
Do not use Tongkat Ali (Eurycoma longifolia) in this 58-year-old patient with diabetes on insulin, CKD, and hypertension. The supplement poses significant safety concerns that outweigh any potential benefits, particularly given this patient's complex medical profile.
Critical Safety Concerns
Genotoxicity Evidence
The European Food Safety Authority (EFSA) concluded in 2021 that Tongkat Ali has the potential to induce DNA damage, particularly in tissues at first sites of contact (stomach and duodenum). In vivo testing showed positive results for DNA damage at 2,000 mg/kg body weight, with histopathological evaluation confirming genotoxicity rather than simple cytotoxicity 1. The EFSA explicitly stated that "the safety of NF has not been established under any condition of use" 1.
Cardiovascular Risk
A 2025 case report documented new-onset atrial flutter in a 71-year-old man following Tongkat Ali supplementation, representing the first documented cardiac arrhythmia case in the literature 2. For a patient already managing hypertension and at high cardiovascular risk due to diabetes and CKD, introducing a supplement with documented arrhythmogenic potential is contraindicated.
Lack of Safety Data in High-Risk Populations
No studies have evaluated Tongkat Ali safety specifically in patients with:
- Chronic kidney disease (potential accumulation of metabolites)
- Insulin-dependent diabetes (unknown interactions with glucose metabolism)
- Concurrent use of antihypertensive medications (particularly ACE inhibitors or ARBs, which this patient should be taking per guidelines 3, 4)
Why This Patient's Profile Increases Risk
Existing Medication Burden
According to KDIGO 2020 guidelines, this patient should be on 3:
- ACE inhibitor or ARB (titrated to maximum tolerated dose for renal protection)
- Insulin (with careful monitoring to avoid hypoglycemia)
- Antihypertensive agents (target BP 140/90 mm Hg per Endocrine Society guidelines 5)
- Potentially SGLT2 inhibitors if eGFR ≥30 mL/min/1.73 m²
Adding Tongkat Ali creates unpredictable drug-supplement interactions, particularly concerning given the supplement's effects on testosterone and potential hormonal cascades that could affect glucose metabolism and blood pressure regulation.
Renal Impairment Considerations
While one small study showed no adverse changes in renal function tests at "normal daily dose" 6, this was in healthy individuals, not patients with established CKD. The supplement contains multiple bioactive compounds including alkaloids and glycosaponins (40-65%) 1 that require renal clearance. In CKD, accumulation risk is substantial and unpredictable.
Hypoglycemia Risk
The patient is on insulin, which already carries hypoglycemia risk. Tongkat Ali's effects on metabolism and potential interactions with insulin are unknown. The Endocrine Society emphasizes that "of critical importance is the avoidance of hypoglycemia, which can have devastating outcomes in older patients" 5.
Alternative Evidence-Based Approaches
Instead of Tongkat Ali, focus on proven interventions for this patient's conditions:
For Diabetes and CKD Management 3:
- Metformin (if eGFR ≥30 mL/min/1.73 m²)
- SGLT2 inhibitors (proven cardiovascular and renal benefits)
- Optimized insulin regimen with frequent glucose monitoring
- ACE inhibitor or ARB at maximum tolerated dose
For Hypertension 5, 4:
- Target BP 140/90 mm Hg (or 130/80 mm Hg if progressing CKD with albuminuria)
- ACE inhibitor or ARB as first-line
- Add thiazide diuretic or calcium channel blocker as needed
For Overall Health:
- Lifestyle modification: diet high in vegetables, fruits, whole grains, fiber; lower in processed meats and refined carbohydrates 7
- Smoking cessation if applicable 4
- Regular monitoring: HbA1c every 3-6 months, serum creatinine and potassium within 2-4 weeks of medication changes 3
Clinical Pitfalls to Avoid
- Do not assume "natural" means safe: Tongkat Ali has documented genotoxic and arrhythmogenic potential
- Do not underestimate drug-supplement interactions: This patient's medication regimen is complex and evidence-based; adding unproven supplements risks destabilization
- Do not ignore the lack of safety data: No studies exist in patients with this specific combination of conditions
- Do not prioritize unproven supplements over evidence-based therapies: Focus on optimizing guideline-directed medical therapy
The risk-benefit analysis clearly favors avoiding Tongkat Ali in this patient. Direct the patient toward evidence-based interventions that have proven mortality and morbidity benefits in diabetes, CKD, and hypertension.